Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Accolade (DE:4NE1)
FRANKFURT:4NE1
Accolade (4NE1) Stock Price & Analysis
0 Followers
4NE1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€6.05 - €13.60
Previous Close€7.55
Volume0.00
Average Volume (3M)N/A
Market Cap
€570.65M
Enterprise Value€574.55M
Total Cash (Recent Filing)$237.03M
Total Debt (Recent Filing)$241.21M
Price to Earnings (P/E)N/A
Beta0.98
Next Earnings
Jun 27, 2024EPS Estimate
-€0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,356,908
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-33.89
Price to Sales (P/S)4.74
Price to Cash Flow (P/CF)29.30
P/FCF Ratio102.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit2.99
Enterprise Value/Ebitda-11.92
Forecast
1Y Price Target
€12.14Price Target Upside66.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Accolade News
PremiumCompany Announcements
Accolade, Inc. at a Crossroads: Navigating Regulatory Risks in AI Integration
Bulls Say, Bears Say
Bulls Say
Client AcquisitionThe addition of Arkansas Blue Cross Blue Shield as a client demonstrates momentum in the health plan market.
Profitability OutlookForecast for adjusted EBITDA margin in FY25 shows improvement, suggesting better profitability ahead.
Revenue GrowthMultiple vectors point toward the higher end of the annual 16-21% revenue growth guidance range.
Bears Say
Business PerformanceGross Dollar Retention at 89% fell short of expectations, which partly explains why the actual ACV did not meet projections.
Financial ForecastRevenue and EBITDA estimates for FY26 are below consensus estimates.
Revenue GuidanceFY25 revenue growth guidance has been revised down from ~20% to 18.5% year-over-year.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
9.86% Other Institutional Investors
90.14% Public Companies and
Individual Investors
4NE1 FAQ
What was Accolade’s price range in the past 12 months?
Accolade lowest stock price was €6.05 and its highest was €13.60 in the past 12 months.
What is Accolade’s market cap?
Currently, no data Available
When is Accolade’s upcoming earnings report date?
Accolade’s upcoming earnings report date is Jun 27, 2024 which is in 56 days.
How were Accolade’s earnings last quarter?
Accolade released its earnings results on Apr 25, 2024. The company reported -€0.093 earnings per share for the quarter, beating the consensus estimate of -€0.106 by €0.012.
Is Accolade overvalued?
According to Wall Street analysts Accolade’s price is currently Undervalued.
Does Accolade pay dividends?
Accolade does not currently pay dividends.
What is Accolade’s EPS estimate?
Accolade’s EPS estimate is -€0.45.
How many shares outstanding does Accolade have?
Currently, no data Available
What happened to Accolade’s price movement after its last earnings report?
Accolade reported an EPS of -€0.093 in its last earnings report, beating expectations of -€0.106. Following the earnings report the stock price went down -12.717%.
Which hedge fund is a major shareholder of Accolade?
Among the largest hedge funds holding Accolade’s share is ARK Investment Management LLC. It holds Accolade’s shares valued at 82M.
---
Accolade Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€12.14 (66.31% Upside)
€12.14 (66.31% Upside)
Blogger Sentiment
Bullish
DE:4NE1 Sentiment 75%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.46%
12-Months-Change
Fundamentals
Return on Equity
-21.71%
Trailing 12-Months
Asset Growth
-12.73%
Trailing 12-Months
Company Description
Accolade
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. it generates revenue through providing personalized health guidance solutions to members.
---
4NE1 Company Deck
---
4NE1 Earnings Call
Q4 2024
0:00 / 0:00
---
4NE1 Stock 12 Months Forecast
Average Price Target
€12.14
▲(66.31% Upside)
Technical Analysis
Accolade
―
Aclaris Therapeutics
―
Acadia Healthcare
―
Achieve Life Sciences
―
ACADIA Pharmaceuticals
―
Best Analysts Covering 4NE1
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-11.82%
reiterated a buy rating 7 days ago
Copying Ryan MacDonald's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -11.82% per trade.
---